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Persistence of virus-specific immune responses
in the central nervous system of mice after
West Nile virus infection
Barbara S Stewart1,2, Valerie L Demarest1, Susan J Wong1,2, Sharone Green3, Kristen A Bernard1,2,4*
Abstract
Background: West Nile virus (WNV) persists in humans and several animal models. We previously demonstrated
that WNV persists in the central nervous system (CNS) of mice for up to 6 months post-inoculation. We
hypothesized that the CNS immune response is ineffective in clearing the virus.
Results: Immunocompetent, adult mice were inoculated subcutaneously with WNV, and the CNS immune
response was examined at 1, 2, 4, 8, 12 and 16 weeks post-inoculation (wpi). Characterization of lymphocyte
phenotypes in the CNS revealed elevation of CD19+ B cells for 4 wpi, CD138 plasma cells at 12 wpi, and CD4+ and
CD8+ T cells for at least 12 wpi. T cells recruited to the brain were activated, and regulatory T cells (Tregs) were
present for at least 12 wpi. WNV-specific antibody secreting cells were detected in the brain from 2 to 16 wpi, and
virus-specific CD8+ T cells directed against an immunodominant WNV epitope were detected in the brain from
1 to 16 wpi. Furthermore, these WNV-specific immune responses occurred in mice with and without acute clinical
disease.
Conclusions: Virus-specific immune cells persist in the CNS of mice after WNV infection for up to 16 wpi.
Background
West Nile virus (WNV), a member of the family Flavi-
viridae, is a positive-sense, single-stranded RNA virus,
which is maintained in a mosquito-bird enzootic cycle.
Upon incidental infection with WNV, approximately
20% of humans experience a self-limiting illness called
“West Nile fever”, and less than 1% develop West Nile
neuroinvasive disease (WNND) [1]. WNND is character-
ized by encephalitis, myelitis, and/or meningitis and can
lead to death [2-4]. In addition to acute disease, long
term sequelae occur in individuals recovering from
West Nile fever and WNND [3,5-8]. The underlying
mechanisms resulting in these sequelae remain unclear,
but may partly be due to viral persistence.
Several studies provide evidence for persistence of
WNV in humans. WNV RNA persists in urine of conva-
lescent patients for as long as 6.7 years after disease
onset [9]. In blood donors, WNV RNA is detected in
blood as long as 104 days after index donation [10].
WNV-specific immunoglobulin M (IgM) persists in
serum of patients with West Nile disease and WNV-
positive blood donors for as long as 11 to 16 months
[10-13]. In addition, IgM persists in cerebrospinal fluid
of patients with WNND for as long as 5 months [14].
The long term persistence of IgM suggests that virus
and/or viral antigen persists in the periphery and possi-
bly in the CNS of immunocompetent humans infected
with WNV.
The goal of the current study was to further our
understanding of WNV persistence, using a mouse
model in which WNV RNA persists in the CNS for up
to 6 months post-inoculation [15]. We characterized the
lymphocyte populations present in the CNS at various
times post-inoculation. CD138+ plasma cells and CD4+
and CD8+ T cells were elevated in the CNS of mice for
at least 3 months after infection with WNV. In addition,
WNV-specific plasma cells and WNV-epitope specific
CD8+ T cells were present for up to 16 wpi, suggesting
that WNV is able to persist in the CNS despite the pre-
sence of virus specific immune cells.* Correspondence: kbernard@vetmed.wisc.edu
1Wadsworth Center, New York State Department of Health, Albany, NY, USA
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Results
We previously showed that WNV RNA persists in the
CNS of C57BL/6 (B6) mice for up to 6 months post-
inoculation, and this persistence occurs in the face of
active inflammation in the brain and a strong serum
antibody response and in mice with subclinical infec-
tion [15]. Our goal in this study was to characterize
this inflammation in the CNS during viral persistence
in our B6 mouse model and to determine if the
immune cells were virus-specific. Brains and spinal
cords were harvested from mice, and the phenotypes
of infiltrating CNS leukocytes were determined at 1, 2,
4, 8, 12 and 16 wpi. Since not all B6 mice exhibit
West Nile disease [16], we distributed mice that had
been sick during acute infection (7 to 14 days post-
inoculation) evenly throughout each time point within
an individual study (noted as open symbols in figures)
in order not to bias the results. Although the numbers
of sick mice were small, we did not observe any con-
sistent correlation between disease and any cellular
parameter.
For all flow cytometric analyses, cells were gated on the
entire population of CD45+ cells, a pan-leukocyte marker.
This population included a CD45low population, which
are quiescent resident microglial cells, and a CD45high
population, which are activated resident microglial cells
and infiltrating leukocytes (Figure 1A and 1B). This gat-
ing ensured that differences between WNV-inoculated
mice and mock-inoculated mice were not solely due to
activated microglial cells, but due to infiltrating leuko-
cytes and/or expansion of microglial cells.
Phenotype of lymphocytes in the CNS
Elevated numbers of CD45+ cells were observed in the
brains of WNV-inoculated mice compared to mock-
inoculated mice (Figure 1C). WNV-inoculated mice had
20- to 30-fold more CD45+ cells in the CNS than mock-
inoculated mice at 1, 2, and 4 wpi (P = 0.002). Similar
levels of CD45+ cells were observed in the spinal cords
of WNV-inoculated mice (data not shown). After 4 wpi,
the number of CD45+ cells in the brains decreased with
2- to 7-fold more CD45+ cells in the brains of WNV-
inoculated mice than in mock-inoculated mice, but
these differences were not statistically different. In addi-
tion, there was more variability from mouse-to-mouse at
the later time points, which was consistent with our
previous results of variable WNV RNA persistence and
histologic lesions after 4 wpi [15].
We previously observed lymphocytic, plasmacytic
inflammation in the brains of mice persistently infected
with WNV RNA for up to 4 months post-inoculation
[15]; therefore, we analyzed the leukocytes from brains
for lymphocyte markers (Figure 2A). WNV-inoculated
mice had significantly higher numbers of CD19+ B cells
for 1 to 4 wpi (P = 0.002) and CD138+ plasma cells at
12 wpi (P = 0.02) in brains compared to mock-inocu-
lated mice (Figure 2B and 2C). CD19+ B cells declined
over time after 4 wpi (Figure 2B). The highest numbers
of CD138+ plasma cells were observed at 1 and 2 wpi
with geometric means of approximately 103.5 cells per
brain for WNV-inoculated mice, and plasma cells in the
brain slowly declined through 16 wpi (Figure 2C). Simi-
lar levels of CD19+ B cells and CD138+ plasma cells
were observed in the spinal cords of WNV-inoculated
mice (data not shown).
WNV-inoculated mice had significantly higher
numbers of both CD8+ and CD4+ T cells in their brains
than mock-inoculated mice from 1 through 12 wpi
(P = 0.002-0.004; Figure 2D and 2E). Both CD8+ and
Figure 1 WNV infection induces leukocyte infiltration in the
CNS. Adult, female B6 mice were inoculated SC with diluent (mock)
or 103 PFU of WNV in the left rear footpad. At various times post-
inoculation, two mock-inoculated and four WNV-inoculated mice
were sacrificed and perfused with perfusion buffer. CNS
mononuclear cells were collected, and flow cytometry was
performed for various cell markers. Representative scatter plots and
gating for flow cytometry are shown for leukocytes isolated from
brains of (A) a mock-inoculated mouse and (B) a WNV-inoculated
mouse. (C) Numbers of CD45+ cells are reported per brain. Each
data point represents an individual mouse, and solid horizontal lines
represent the geometric means. Open symbols indicate mice that
showed clinical signs of disease during acute illness. Two
independent studies were performed for 1, 2, 4, 8 and 12 wpi, and
these data were analyzed by Mann-Whitney U tests with P values
indicated by: 0.001 < ** ≤0.01.
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CD4+ T cells remained constant in the brain through
week 4 with geometric means of approximately 104 cells
per brain for WNV-inoculated mice compared to
approximately 102 cells per brain in mock-inoculated
mice. After 4 wpi, numbers of T cells in the brain
declined to approximately 103 cells per brain for WNV-
inoculated mice. Similar results were found in the spinal
cord except that infiltration was delayed by one week
for CD4+ T cells (peaking at 2 wpi) compared to infil-
tration in the brain (data not shown).
Activated T cells and Tregs in the CNS
Elevated numbers of T cells were present in the CNS,
but we previously showed that clearance of WNV RNA
was delayed until after 2 months post-inoculation [15].
Thus, we questioned if the T cells in the CNS were acti-
vated, and if Tregs were present. We examined CD8+
and CD4+ T cells in the CNS for two activation mar-
kers, CD69 and CD25 (Figure 3A). Activated CD8+ and
CD4+ T cells were observed by 1 wpi with approxi-
mately 50% of these cells expressing at least one activa-
tion marker (Figure 3B and 3C). The percentage of
activated CD8+ T cells peaked at approximately 90% at
4 wpi and remained fairly constant through 16 wpi
(Figure 3B). The percentage of activated CD4+ T cells
reached 70% at 2 wpi and 90% at 12 wpi (Figure 3C). In
summary, CD8+ and CD4+ T cells in the brain were
activated for at least 16 wpi.
We hypothesized that Tregs may delay viral clear-
ance by inhibiting the CD8+ T cell response; therefore,
Figure 2 B cells and T cells persist in the CNS of WNV-inoculated mice. Adult, female B6 mice were inoculated SC with diluent (mock) or 103
PFU of WNV in the left rear footpad. At various times post-inoculation, two mock-inoculated and four WNV-inoculated mice were sacrificed and
perfused with perfusion buffer. CNS mononuclear cells were collected, and flow cytometry was performed for various cell markers. Cells were gated
on the CD45+ population as shown in Figure 1. (A) Representative scatter plots are shown for CD19+, CD138+, CD4+ and CD8+ cells from WNV-
inoculated mice. The numbers of (B) CD19+, (C) CD138+, (D) CD8+, and (E) CD4+ cells per brain are shown at various times post-inoculation. Each
data point represents an individual mouse, and solid horizontal lines represent the geometric means. Open symbols indicate mice that showed
clinical signs of disease during acute illness. Two independent studies were performed for 1, 2, 4, 8 and 12 wpi for B, D and E and for 1 and 12 wpi
for C, and these data were analyzed by Mann-Whitney U tests with P values indicated by: 0.001 < ** ≤0.01 and 0.01 < * ≤0.05.
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we examined Tregs, defined as cells expressing CD4,
CD25, and Foxp3 [17], in the brains of mice over time
(Figure 4A). We observed Tregs as early as 1 wpi
in the brains of WNV-inoculated mice (50-fold
greater than in mock-inoculated mice; P = 0.002) and
persisting for at least 12 wpi (8-fold greater than in
mock-inoculated mice; P = 0.008) (Figure 4B). The
percentages of CD4+ T cells exhibiting the CD25
+Foxp3+ phenotype increased 3-fold from 1 to 12 wpi
(P = 0.03) (Figure 4C). The highest percentage of
Tregs at 12 wpi (mean of 11.4%) correlated with the
highest percentage of activated CD4+ T cells (Figure
3C) and relatively high levels of CD4+ T cells in brains
of WNV-inoculated mice (Figure 2E).
WNV-specific immune cells in the CNS
In our phenotypic analysis, we observed CD138+ plasma
cells, and activated CD8+ and CD4+ T cells in the CNS
of WNV-inoculated animals for at least 12 wpi. How-
ever, despite an active immune response in the CNS,
our previous results showed that WNV RNA continues
to persist in the CNS of approximately half of the mice
at 3 months post-inoculation and a quarter of the mice
at 4 months post-inoculation [15].
In order to determine whether the inflammatory
response that we detected was WNV-specific, we exam-
ined the humoral response by performing ELISPOT
assays for WNV-specific IgM and IgG antibody secret-
ing cells (ASC) in brains and spleens. At 1 wpi, IgM
ASC specific for WNV were detected at relatively high
numbers in the spleen (average = 150 IgM ASC/106
cells), but none were detected in the brain (Figure 5A
and 5B). By 2 wpi, seven of eight WNV-inoculated mice
had IgM ASC in brains and spleens (average = 10 IgM
ASC/106 cells). By 4 wpi, no IgM ASC were detected in
the brains or spleens (data not shown), which was most
likely due to class switching to IgG. WNV-specific IgG
ASC were first detected in spleens at 1 wpi and in
brains at very low levels at 2 wpi (Figure 5C and 5D).
By 4 wpi, there were 5-fold more IgG ASC in brains
(average of 100 IgG ASC/106 cells) than in spleens
(average of 20 IgG ASC/106 cells). The numbers of
WNV-specific IgG ASC remained relatively constant in
the two tissues through 16 wpi except at 8 wpi when
Figure 3 T cells are activated in the CNS of WNV-inoculated mice. Adult, female B6 mice were inoculated SC with 103 PFU of WNV in the
left rear footpad. At various times post-inoculation, four WNV-inoculated mice were sacrificed and perfused with perfusion buffer. CNS
mononuclear cells were collected, and flow cytometry was performed for various cell markers. Cells were gated on the CD45+ population as
shown in Figure 1. (A) Representative scatter plots are shown for activation markers, CD69 or CD25, on cells gated for the CD4+ or CD8+
population from WNV-inoculated mice. The percentage of (B) CD8+ T cells and (C) CD4+ T cells expressing either CD69 or CD25 in the brains of
WNV-inoculated mice are shown at various times post-inoculation. Bars and error bars represent the average and SD of four mice.
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only one of eight mice had detectable IgG ASC in the
spleen. Seven of eight mice were positive for IgG ASC
in the spleens at 12 and 16 wpi, suggesting that the
immune response was stimulated between 8 and 12 wpi.
We confirmed the presence of intrathecal antibody in
the CNS by measuring antibody specific for WNV E
and NS5 proteins in supernatants from CNS homoge-
nates. The kinetics of WNV-specific antibodies in the
brain were very similar to the kinetics of the antibody
response measured in the serum; however, the levels of
antibody were approximately 50-fold lower in brains
than in sera (Figure 6). Antibodies to E and NS5 were
first observed in brains at 1 wpi in 25% and 12% of
mice, respectively (Figure 6C and 6D). At this time
point, ASC were not observed in brains (Figure 5B and
5D), which is most likely due to differences in assay sen-
sitivity. Antibodies to E and NS5 were also observed in
spinal cords of mice, and the kinetics and levels of anti-
bodies were very similar to the results in the brains
(data not shown).
We next examined the WNV-specific CD8+ T cell
response to an immunodominant WNV epitope,
SSVWNATTA in NS4B [18,19], using MHC class I
dimer staining in brains and spleens (Figure 7A and 7B).
WNV epitope-specific CD8+ T cells were significantly
higher in the brains of WNV-inoculated mice compared
to mock-inoculated mice from 1 to 12 wpi (P = 0.004-
0.005; Figure 7C). WNV epitope-specific CD8+ T cells
peaked at 2 wpi (average of 300 cells per brain) (Figure
7C), representing approximately 5% of all CD8+ T cells
in the brain (data not shown). By 16 wpi in the brain,
WNV epitope-specific CD8+ T cells were detected in
four of eight mice. In the spleen, WNV epitope-specific
CD8+ T cells were significantly higher in WNV-inocu-
lated mice compared to mock-inoculated mice from 1
to 16 wpi (P = 0.004-0.02; Figure 7D). In contrast to the
brain, epitope-specific CD8+ T cells in the spleen were
highest at 1 wpi and declined through 8 wpi (Figure
7D). At 12 and 16 wpi, there was an increase in WNV
epitope-specific CD8+ T cells in the spleen, suggesting
that the immune response was stimulated between 8
and 12 wpi as was observed in the independent study
that measured ASC in the spleen (Figure 5C).
Discussion and Conclusions
Our studies are the first to demonstrate the retention of
WNV-specific immune cells in the CNS in an immuno-
competent mouse model. Immune cells were recruited
and maintained in the CNS for at least 12 wpi, including
plasma cells, activated T cells and Tregs. Additionally,
WNV-specific ASC and CD8+ T cells specific for a
dominant epitope of WNV were detected in the brains
of mice for up to16 wpi, including mice without clinical
disease. The presence of specific immune cells is consis-
tent with our previous studies, which showed that WNV
persists in the CNS in a subset of animals as infectious
virus for 4 months post-inoculation and viral RNA for
6 months post-inoculation [15]. Overall these results
suggest that the presence of virus-specific immune cells
in the CNS is not sufficient for viral clearance.
Figure 4 Tregs are present in the CNS of WNV-inoculated mice.
Adult, female B6 mice were inoculated SC with diluent (mock) or
103 PFU of WNV in the left rear footpad. At various times post-
inoculation, two mock-inoculated and four WNV-inoculated mice
were sacrificed and perfused with perfusion buffer. CNS
mononuclear cells were collected, and flow cytometry was
performed for various cell markers. Cells were gated on the CD45+
population as shown in Figure 1. (A) Representative scatter plot is
shown for Treg markers, Foxp3 and CD25, on cells gated for the
CD4+ population from a WNV-inoculated mouse. (B) The numbers
of CD4+/Foxp3+/CD25+ cells per brain are shown at various times
post-inoculation. Each data point represents an individual mouse,
and solid horizontal lines represent the geometric means. Open
symbols indicate mice that showed clinical signs of disease during
acute illness. The data point on the x-axis is negative. Two
independent studies were performed for 1 and 12 wpi, and these
data were analyzed by Mann-Whitney U tests with P values
indicated by: 0.001 < ** ≤0.01. (C) The percentage of CD4+ cells
expressing Foxp3 and CD25 in the brains of WNV-inoculated mice is
shown at various times post-inoculation. Each data point represents
an individual mouse, and solid horizontal lines represent the means.
The groups from each time point were significantly different by a
Kruskal-Wallis test (P = 0.05), and the group at 12 wpi was
significantly different from the groups at 1, 2 and 4 wpi by Mann-
Whitney U tests (P < 0.05).
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Our current study was limited in that we were unable
to correlate WNV persistence and cellular phenotype
in the CNS within the same individual mouse because
we harvested the entire brain and spinal cord for cell
analysis. On the other hand, we have used identical
methods, including mouse strain, sex and age, viral
dose, inoculation route, and WNV strain, as our pre-
vious study [15], which has been repeated with very
similar results in a number of independent studies.
Thus, although we do not have correlative data, we
have strong evidence that WNV persists as infectious
virus in all mice at 1 month post-inoculation and as
RNA in approximately 25% of mice at 4 months post-
inoculation.
We observed no obvious deficiencies in the immune
cell infiltrate in the CNS to account for the observed
viral persistence in B6 mice [15]. Previous studies have
shown that T cells play a crucial role in clearing WNV
from CNS tissues. Mice that lack CD8+ T cells have
higher viral burdens, and infectious virus can be recov-
ered for several weeks following initial infection [20,21].
Additionally, CD4+ T cells are important for sustaining
and maintaining primary CD8+ T cells responses in the
brain [22]. B cells and antibody play a critical role dur-
ing WNV infection. μMT mice, which are deficient in B
cells, have higher viremia and viral loads in the CNS,
suggesting that B cells directly limit the early replication
of virus in the CNS [23]; however, CD8+ T cells are
responsible for viral clearance in the CNS tissues [20].
In our studies, elevated numbers of CD4+ and CD8+ T
cells, and plasma cells were present in the CNS during
the time course of the studies.
Figure 5 WNV-specific ASC persist in brains for at least 16 wpi in WNV-inoculated mice. Adult, female B6 mice were inoculated SC with
diluent (mock) or 103 PFU of WNV in the left rear footpad. At various times post-inoculation, two mock-inoculated and four WNV-inoculated
mice were sacrificed and perfused with perfusion buffer. Brain and splenic mononuclear cells were collected, and ELISPOT assays for ASC were
performed using WNV and irrelevant antigens. The numbers of IgM ASC in the (A) spleen and (B) brain and the numbers of IgG ASC in the
(C) spleen and (D) brain are reported. Each data point represents a single mouse, and solid horizontal lines represent the means. Open symbols
indicate mice that displayed signs of clinical disease during the acute illness. Data points on the x-axis are negative. Data are from one to two
independent studies. Results from mock-inoculated mice were negative and are not shown.
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In addition, we demonstrated that T cells in the brains
of mice had early (CD69) and late (CD25) activation
markers through 16 wpi. Typically, CD69 is transiently
upregulated during early T cell activation; however, in
our studies, CD69 was chronically expressed on both
CD4+ and CD8+ T cells in the brain, which suggests
either an ongoing stimulation of resident T cells or
fresh recruits infiltrating into the CNS. The continual
expression of CD69 on T cells occurs in other viral
models, including dengue, neurotropic influenza and
mouse hepatitis viruses, and is a common feature of
CD8+ T cells retained in the CNS [24-26]. It has been
postulated that the chronic expression of CD69 identi-
fies cells that are in a state of anergy or non-responsive-
ness due to prolonged antigen exposure [24,25,27,28]. In
our studies, both CD69 and CD25 expressing T cells
were recruited and maintained at high percentages in
the CNS, suggesting that there is ongoing stimulation of
these cells via virus and/or antigen. Alternatively, there
may be bystander activation of non-specific cells and/or
a failure to turn off the activation state.
We observed long term persistence of WNV-specific
CD8+ T cells in brains of mice, which supports the
model of ongoing stimulation. At the end of the studies
(16 wpi), half of the mice had detectable CD8+ T cells
specific for an immunodominant epitope in WNV in the
brain. These findings are consistent with our previous
finding that WNV RNA and infectious virus persists in
the CNS at 16 wpi in 25% and 12% of mice, respectively
[15]. Furthermore, WNV-specific ASC were first
Figure 6 WNV-specific antibodies are present in brains for at least 16 wpi in WNV-inoculated mice. Adult, female B6 mice were
inoculated SC with diluent (mock) or 103 PFU of WNV in the left rear footpad. At various time points post-inoculation, two mock-inoculated and
four WNV-inoculated mice were sacrificed and perfused with perfusion buffer. (Aand B) Sera and (Cand D) supernatant from homogenized brain
were tested for antibodies against (Aand C) WNV E and (Band D) WNV NS5 proteins using MIA. Each data point represents an individual mouse,
and solid horizontal lines represent the means. Open symbols indicate mice that displayed signs of clinical disease during the acute illness. Data
points on the x-axis are negative. Data are from one to two independent studies. Results from mock-inoculated mice were negative and are not
shown.
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detected in brains at 2 wpi and persisted for up to
16 wpi.
The trafficking and persistence of ASC in the CNS
also occurs in other viral models. We observed that
antiviral IgM and IgG ASC in the spleen preceded the
detection of ASC in the brain, suggesting that B cells
from the periphery are activated and subsequently traffic
to the CNS where they differentiate into ASC, as occurs
for mouse hepatitis virus [29]. Similar to our results,
virus-specific ASC are detected in mouse brains for one
year after infection with Sindbis virus [30] and for 90
days after infection with mouse hepatitis virus [29,31].
Since we detected WNV RNA for up to six months in
the CNS [15], the retention of WNV-specific ASC
within the CNS suggests that these cells contribute to
continual viral suppression via long term production of
intrathecal antibody as observed with other encephalitic
viruses [30-32].
The persistence of WNV in the CNS in the face of a
specific local immune response raises the following
question: why is viral clearance from the CNS delayed
for 6 months in a subset of animals? We propose that
the persistent WNV infection in the CNS is a low level,
smoldering infection that is prevented from spreading
by the presence of WNV-specific intrathecal antibody.
Although T cells are activated, and virus-specific CD8+
T cells are present, we speculate that they are inhibited
in order to prevent excessive damage to neurons. This
inhibition may be due to Tregs, which we observed in
the CNS during the entire course of our studies. Lower
levels of Tregs are associated with greater disease in
humans and mice [33], and thus, Tregs may be impor-
tant in inhibiting immunopathology in the CNS and
allowing viral persistence. Future studies will focus on
testing this model and furthering our understanding of
the CNS immune response during persistent viral
infections.
Methods
Virus and cells
WNV was produced from a full-length cDNA clone of a
strain isolated in 2000 in New York as previously
described [34]. Viral titers of stocks were determined by
plaque assay on Vero cells (ATCC #CCL-81) as pre-
viously described [16]. Serum-free WNV stocks were
harvested from Vero cells incubated in VP medium
(Gibco® Invitrogen, Carlsbad, CA).
Mice
Five-week-old female B6 mice (Taconic, Germantown,
NY) were acclimatized for at least one week in the BSL-
3 facility. At six- to seven-weeks of age, mice were
inoculated subcutaneously (SC) in the left rear footpad
with diluent (mock) or 103 plaque forming units (PFU)
of WNV as previously described [16]. After inoculation,
all mice were observed for clinical disease daily for the
entire study, and they were weighed daily for at least
2 wpi and one to three times per week for the remain-
der of the study. Clinical signs included ruffled fur,
Figure 7 WNV-specific CD8+ T cells persist in brains for up to
16 wpi in WNV-inoculated mice. Adult, female B6 mice were
inoculated SC with diluent (mock) or 103 PFU of WNV in the left
rear footpad. At various times post-inoculation, two mock-
inoculated and four WNV-inoculated mice were sacrificed and
perfused with perfusion buffer. CNS and splenic mononuclear cells
were collected, and flow cytometry was performed for CD45, CD8
and MHC class I dimer for a WNV dominant epitope (SSVWNATTA)
and an irrelevant epitope. Cells were gated on the CD45+
population as shown in Figure 1. Representative scatter plots are
shown for CD8 and WNV-specific dimer in the (A) brain and (B)
spleen from WNV-inoculated mice. The numbers of CD8+ T cells in
the (C) brain and the percentages of CD8+ T cells in the (D) spleen
that were specific for the WNV epitope are reported. Values for
specific CD8+ T cells were calculated by subtracting background
values for the irrelevant peptide from values for the WNV peptide.
Each data point represents an individual mouse, and solid horizontal
lines represent the geometric means in (C) and means in (D). Open
symbols indicate mice that displayed signs of disease during acute
illness. Data points on the x-axis are negative. Two independent
studies were performed, and these data were analyzed by Mann-
Whitney U tests with P values indicated by: 0.001 < ** ≤0.01 and
0.01 < * ≤0.05.
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hunching, ataxia, and weakness. A mouse was consid-
ered to have clinical West Nile disease if at least one of
the following criteria was met: 1) ≥10% weight loss; 2)
clinical signs for at least two days. Mice that exhibited
severe disease were euthanized. No clinical signs or
weight loss were observed in mock-inoculated mice. All
WNV-inoculated mice were seropositive for WNV at
the time of sacrifice. At various times post-inoculation,
mice were sacrificed and transcardially perfused with 60
ml phosphate buffered saline (PBS) plus 1% fetal bovine
serum (FBS) [perfusion buffer], and tissues were har-
vested. All studies were approved by the Institutional
Animal Care and Use Committee and followed criteria
established by the National Institutes of Health.
Isolation of mononuclear cells
Brains, spinal cords, and spleens were homogenized
between glass slides with 10 ml of RPMI 1640 (RPMI,
Gibco® Invitrogen) plus 5% FBS. Spinal cords from
four WNV-inoculated mice were pooled in order to
obtain enough cells for analysis. Homogenates were
pressed through a 100 micron cell strainer and centri-
fuged at 1200 × g for 5 minutes at 4°C. The cell pellet
was resuspended in RPMI plus 5% FBS, placed over a
30/70% Percoll (Sigma-Aldrich, St. Louis, MO) step
gradient, and centrifuged at 400 × g for 25 minutes at
4°C. The mononuclear cells were collected at the inter-
face, washed two times, and resuspended in RPMI plus
5% FBS.
Flow cytometry
For cell surface analysis, mononuclear cells (106 cells/
test) were incubated with Fc block (BD Biosciences, San
Jose, CA) and stained for surface antigen with two or
more fluorochrome-labeled monoclonal antibodies
directed against CD4, CD8, CD19, CD138, (BD Bios-
ciences), CD25, CD45, Foxp3 (eBioscience, San Diego,
CA), and CD69 (Caltag, Burlingame, CA). Cells that
were stained for CD4 and CD25 were permeabilized and
intracellularly stained using a Foxp3 staining buffer kit
(eBioscience) according to manufacturer’s protocol.
Cells were fixed with 2% paraformaldehyde at 4°C over-
night prior to analysis with FACSAria flow cytometer
(BD Biosciences). For CNS samples, one million live
events were counted. For splenocytes, 75,000 live events
were counted. For analysis, all samples were first gated
on CD45 as described previously for mouse brain sam-
ples [29]. Isotype matched irrelevant antibodies were
used as controls. Data were analyzed using FlowJo soft-
ware (v.7, Tree Star, Ashland, OR).
ELISPOT assay for ASC
For WNV-specific ELISPOT assays for ASC, plates (96-
well nitrocellulose; Millipore, Billerica, MA) were coated
with serum-free WNV (106 PFU/well) or conditioned
medium (irrelevant antigen) and then blocked with
RPMI plus 10% FBS. Mononuclear cells were isolated
from brains and spleens of mock- or WNV-inoculated
mice as described above, added to wells (6.25 × 103 to 4
× 105 cells/well) in triplicate, and incubated overnight.
ASC spots were developed by sequential addition of bio-
tinylated anti-IgM or anti-IgG (Vector Laboratories,
Burlingame, CA), horseradish peroxidase-conjugated
strepavidin (Vector Laboratories), and 3-amino-9-ethyl
carbazole substrate (BD Biosciences) and counted using
a dissecting microscope. The numbers of specific ASC
were determined by subtraction of the average number
of spots in the irrelevant antigen wells (range: 0-2 in
brains, 0-14 in spleens) from the average number of
spots in the WNV antigen wells.
Microsphere immunoassay (MIA) for WNV-specific
antibody in tissues
Sera, brains and spinal cords were harvested from
mock- or WNV-inoculated mice that were sacrificed
and perfused at various times post-inoculation as
described above. Tissues were processed as previously
described [16]. Briefly, tissues were harvested and
weighed, and RPMI was added to make a 20% homoge-
nate. Sera and tissue supernatants were heat-inacti-
vated for 1 hour at 56°C and tested at 1:100 and 1:10
dilutions, respectively, using fluorescent MIA for WNV
envelope (E) and non-structural 5 (NS5) proteins as
previously described [15,35]. Cutoff values for positive
samples were calculated as the average mean fluores-
cence intensity of sera or tissue supernatants from
mock-inoculated mice plus three standard deviations
(Microsoft®Office Excel, Microsoft Corporation,
Seattle, WA).
CD8+ T cell MHC class I dimer staining
Recombinant soluble dimeric mouse H-2Db:Ig (BD Bios-
ciences) was incubated with one of the following pep-
tides at 640 molar excess: the immunodominant WNV
epitope (SSVWNATTA) [18,19] or an irrelevant H-2Db
restricted influenza virus epitope (NP-366-374, Anaspec,
San Jose, CA). Anti-mouse IgG1 (BD Biosciences) and
isotype control were added and incubated sequentially.
Mononuclear cells from brains and spleens of mock- or
WNV-inoculated mice were isolated as described above
and added to the peptide-dimer mixture (106 cells/test).
Cells were then surface stained with anti-CD8 and anti-
CD45 and analyzed by flow cytometry as described
above. Each tissue sample was tested with WNV peptide
and the influenza virus peptide, and the WNV-specific
CD8+ cells were determined by subtraction of back-
ground staining (influenza virus peptide) from the speci-
fic staining (WNV peptide).
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Statistical analysis
Numbers of cells per organ were analyzed for data with
2 independent studies. A one-tailed Mann-Whitney U
test was used to compare data from mock- and WNV-
inoculated mice, and a two-tailed Mann-Whitney U test
was used to compare data from two different time
points for WNV-inoculated mice (GraphPad, San Diego,
CA). A two-tailed Kruskal-Wallis test was used to com-
pare more than two groups (GraphPad). For all analyses,
a P-value of less than 0.05 was considered significant.
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